(Q84388566)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

Juvenile idiopathic arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

juvenile rheumatoid arthritis

5 February 2020

main subject

1 reference

Berent Prakken

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Salvatore Albani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Alberto Martini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

2138-2149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

9783

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

Juvenile idiopathic arthritis

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Juvenile idiopathic arthritis: state of the art and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Using biology of disease to understand and guide therapy of JIA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Heterogeneity in juvenile idiopathic arthritis: impact of molecular profiling based on DNA polymorphism and gene expression patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Psoriatic arthritis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Patients with juvenile psoriatic arthritis comprise two distinct populations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Ankle disease in juvenile idiopathic arthritis: ultrasound findings in clinically swollen ankles.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

An overview of genetics of paediatric rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Juvenile rheumatoid arthritis as a complex genetic trait

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Twins concordant for juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Juvenile rheumatoid arthritis: linkage to HLA demonstrated by allele sharing in affected sibpairs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

A comprehensive review of the genetics of juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Genetics of juvenile idiopathic arthritis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Novel IL10 gene family associations with systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Specific gene expression profiles in systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Divergence in the degree of clonal expansions in inflammatory T cell subpopulations mirrors HLA-associated risk alleles in genetically and clinically distinct subtypes of childhood arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Gene expression profiling in neutrophils from children with polyarticular juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Composition and biological behaviour of immune complexes isolated from synovial fluid of patients with juvenile rheumatoid arthritis (JRA)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Synovial fluid T cell clones from oligoarticular juvenile arthritis patients display a prevalent Th1/Th0-type pattern of cytokine secretion irrespective of immunophenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Synovial expression of osteopontin correlates with angiogenesis in juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Differential expression patterns of recombination-activating genes in individual mature B cells in juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Control of autoimmunity by naturally arising regulatory CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Treating arthritis by immunomodulation: is there a role for regulatory T cells?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

CD30 discriminates heat shock protein 60-induced FOXP3+ CD4+ T cells with a regulatory phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Heat shock protein 60 reactive T cells in juvenile idiopathic arthritis: what is new?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Heat-shock protein 60 as a tool for novel therapeutic strategies that target the induction of regulatory T cells in human arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Heat-shock proteins induce T-cell regulation of chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Systemic JIA: new developments in the understanding of the pathophysiology and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Macrophage activation syndrome: advances towards understanding pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Proinflammatory S100 proteins in arthritis and autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Towards a new clinico-immunopathological classification of juvenile inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Radiologic investigation of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Systematic review of MRI, ultrasound, and scintigraphy as outcome measures for structural pathology in interventional therapeutic studies of knee arthritis: focus on responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Metacarpophalangeal joints in rheumatoid arthritis: delayed gadolinium-enhanced MR imaging of cartilage--a feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Use of unlabelled and off licence drugs in children. Use of unlicensed drugs may be recommended in guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

StaR Child Health: an initiative for RCTs in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Children are not just small adults: the urgent need for high-quality trial evidence in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

International research networks in pediatric rheumatology: the PRINTO perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Preliminary definition of improvement in juvenile arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Burden of childhood-onset arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Leflunomide or methotrexate for juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

1 reference

7 January 2021

Current therapeutic approaches to autoimmune chronic uveitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

The safety profile of biologic therapies for juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Pediatric rheumatology: JIA, treatment and possible risk of malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

The future of pediatric rheumatology: many questions remain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960244-4

7 January 2021

10.1016/S0140-6736(11)60244-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21684384%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference